Targeted therapeutic options and future perspectives for HER2-positive breast cancer

J Wang, B Xu - Signal transduction and targeted therapy, 2019 - nature.com
Over the past 2 decades, there has been an extraordinary progress in the regimens
developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive …

Trastuzumab—mechanism of action and use in clinical practice

CA Hudis - New England journal of medicine, 2007 - Mass Medical Soc
Overexpression of human epidermal growth factor receptor type 2 (HER2) in breast cancer
is associated with decreased overall survival. Trastuzumab, a humanized monoclonal …

Epidermal growth factor receptor (EGFR) signaling in cancer

N Normanno, A De Luca, C Bianco, L Strizzi… - Gene, 2006 - Elsevier
The epidermal growth factor receptor (EGFR) belongs to the ErbB family of receptor tyrosine
kinases (RTK). These trans-membrane proteins are activated following binding with peptide …

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

L Harris, H Fritsche, R Mennel, L Norton… - Journal of clinical …, 2007 - ascopubs.org
Purpose To update the recommendations for the use of tumor marker tests in the prevention,
screening, treatment, and surveillance of breast cancer. Methods For the 2007 update, an …

The HER-2 receptor and breast cancer: ten years of targeted anti–HER-2 therapy and personalized medicine

JS Ross, EA Slodkowska, WF Symmans… - The …, 2009 - academic.oup.com
Learning Objectives Contrast the current strengths and limitations of the three main slide-
based techniques (IHC, FISH, and CISH) currently in clinical use for testing breast cancer …

The EGF receptor family as targets for cancer therapy

J Mendelsohn, J Baselga - Oncogene, 2000 - nature.com
Human carcinomas frequently express high levels of receptors in the EGF receptor family,
and overexpression of at least two of these receptors, the EGF receptor (EGFr) and closely …

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells

MA Molina, J Codony-Servat, J Albanell, F Rojo… - Cancer research, 2001 - AACR
HER2 is a ligand-less tyrosine kinase receptor of the ErbB family that is frequently
overexpressed in breast cancer. It undergoes proteolytic cleavage that results in the release …

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on …

D Cameron, M Casey, M Press, D Lindquist… - Breast cancer research …, 2008 - Springer
Purpose Lapatinib is a small molecule, dual tyrosine kinase inhibitor of epidermal growth
factor receptor (EGFR) and human epidermal growth factor receptor type 2 (HER2). Initial …

The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy

JS Ross, JA Fletcher, GP Linette, J Stec, E Clark… - The …, 2003 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to: Define
the historical background and biological basis of the discovery of the HER-2/neu gene and …

Overcoming trastuzumab resistance in HER2‐positive breast cancer using combination therapy

A Derakhshani, Z Rezaei, H Safarpour… - Journal of cellular …, 2020 - Wiley Online Library
Human epidermal growth factor receptor 2 (HER2)‐positive breast cancer (BC) comprises
around 20–30% of all BC subtypes and is correlated with poor prognosis. For many years …